Perry Andrew 4
4 · G1 Therapeutics, Inc. · Filed Jan 5, 2022
Insider Transaction Report
Form 4
Perry Andrew
Chief Commercial Officer
Transactions
- Award
Common Stock
2022-01-03+6,000→ 6,020 total - Award
Stock Options (Right to buy)
2022-01-03+26,500→ 26,500 totalExercise: $10.69Exp: 2032-01-03→ Common Stock (26,500 underlying)
Footnotes (4)
- [F1]Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2023 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
- [F3]Represents (i) 20 shares of common stock; and (ii) 6,000 RSUs from award granted on January 3, 2022.
- [F4]The shares underlying this option vest as to 25% of the shares on January 3, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.